ロード中...
AT-35 INTERMITTENT HIGH DOSE (PULSATILE) ERLOTINIB FOR EGFRvIII MUTANT RECURRENT MALIGNANT GLIOMAS: A PILOT CLINICAL TRIAL
BACKGROUND: Kinase inhibitors targeting driver mutations are active in several cancers, but have shown only minimal activity against malignant gliomas (MGs). Inadequate drug delivery when administered at the maximum tolerated daily dose may contribute to limited efficacy. Transient inhibition of onc...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217814/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.35 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|